Skip to Main Content

Paper Details

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Clin Cancer Res
45
2022
PATIENTS, PD-L1, Patients, SCCHN, Squamous Cell Carcinoma of the Head and Neck, anti-KIR, anti-PD-1, patients, squamous cell carcinoma of the head and neck
Author NameAffiliation
Ann Marie EgloffBrigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute
Ann Marie EgloffBrigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute
Ravindra UppaluriBrigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute
Robert I HaddadDana-Farber Cancer Institute
Robert I HaddadDana-Farber Cancer Institute
  • 1 - 5

Datasets

Release 1.2